Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Spyre Therapeutics (SYRE) over the last 11 years, with Q1 2025 value amounting to $10000.0.

  • Spyre Therapeutics' Other Non-Current Assets fell 9686.52% to $10000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $10000.0, marking a year-over-year decrease of 9686.52%. This contributed to the annual value of $10000.0 for FY2024, which is 9689.44% down from last year.
  • Spyre Therapeutics' Other Non-Current Assets amounted to $10000.0 in Q1 2025, which was down 9686.52% from $10000.0 recorded in Q4 2024.
  • Spyre Therapeutics' Other Non-Current Assets' 5-year high stood at $1.8 million during Q2 2021, with a 5-year trough of $10000.0 in Q3 2024.
  • Moreover, its 5-year median value for Other Non-Current Assets was $1.3 million (2023), whereas its average is $1.1 million.
  • Per our database at Business Quant, Spyre Therapeutics' Other Non-Current Assets soared by 2306.67% in 2021 and then crashed by 9923.49% in 2024.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Other Non-Current Assets stood at $1.8 million in 2021, then fell by 15.51% to $1.6 million in 2022, then tumbled by 79.27% to $322000.0 in 2023, then tumbled by 96.89% to $10000.0 in 2024, then changed by 0.0% to $10000.0 in 2025.
  • Its last three reported values are $10000.0 in Q1 2025, $10000.0 for Q4 2024, and $10000.0 during Q3 2024.